NCT05050305View on ClinicalTrials.gov

Marizomib Central Nervous System (CNS)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory
Interventions
DRUG

Marizomib

Intravenous Infusion

DRUG

Pomalidomide

Taken orally

DRUG

Dexamethasone

Taken orally

Trial Locations (2)

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER